Brazil IVD Regulation RDC No. 830/2023: Effective Date, Transition Windows and Parallel System

1. Key takeaways

In vitro diagnostic medical devices (IVD, dispositivo médico para diagnóstico in vitro) do not fall under RDC n° 751/2022; they follow RDC n° 830/2023 on their own. That resolution was published on December 11, 2023 in DOU No. 234 and, under Article 71, took effect on June 1, 2024, superseding RDC n° 36/2015 and other old rules.

GRZAN’s judgment: in Brazil the IVD regime is parallel legislation, not a supplementary chapter of the device law. Validity periods and transitional arrangements must be found inside RDC n° 830/2023; a plan that mechanically applies the device provisions will be returned during deficiency review.

2. Legal basis

• Rules for in vitro diagnostic medical devices — RDC n° 830/2023, published in DOU No. 234 of December 11, 2023, Articles 12, 46, 47, 50, 67, 68, 69 (item IX) and 71
• Classification, notification and registration of medical devices, and labeling and instruction-for-use requirements — RDC n° 751/2022, resolution of September 15, 2022, Articles 5, 6, 7 and 60, §1
• Essential safety and performance requirements — RDC n° 848/2024, published in the DOU on March 8, 2024, Articles 81 and 88 (effective 180 days from publication)
• Optimized review procedure — IN n° 290/2024, issued April 4, 2024 and effective June 3, 2024, Articles 2 and 5

3. Expert insights

Why did Brazil legislate for IVDs separately? GRZAN reads it as a matter of differing evaluation logic. Article 81 of RDC n° 848/2024 requires an IVD to demonstrate both analytical performance and clinical performance, and the organization of that evidence differs entirely from the safety rationale for general devices. Forcing both into one technical regulation would leave neither enforceable.

The clause most often missed is the transition. Articles 67 and 68 grant unassayed quality control products and DNA/RNA extraction products a 365-day window from the effective date to complete compliance. Such products are often imported on a small scale by OEMs or research institutions, and companies unaware of the window can only re-file as brand-new applications after it closes. GRZAN’s approach is to list these products on a separate sheet, count the deadline backward from the effective date, and set reminders.

The second pitfall is letting the acceleration window slip by unused. Class III/IV IVDs may use the optimized review route of Article 2 of IN n° 290/2024, which expressly brings IVDs into scope, on the condition that the case rests on prior approval by an equivalent foreign regulatory authority (AREE/EFRA). Companies holding approvals from the US FDA, Japan’s MHLW/PMDA, Australia’s TGA and similar bodies could convert foreign review results into Brazilian time savings, yet the decision is routinely deferred to later.

The third pitfall is misplaced citation. The validity period of an IVD marketing authorization sits in Article 12 of RDC n° 830/2023 — likewise 10 years. GRZAN has seen many documents citing Article 11 of RDC n° 751/2022 instead, and being asked to re-explain the legal basis.

The fourth judgment: IVDs and devices are two parallel systems in Brazil and cannot be substituted for each other. On pathways, device Class I/II notification and Class III/IV registration sit in Articles 6 and 7 of RDC n° 751/2022, while the identically named IVD routes trace back to RDC n° 830/2023 itself. Labeling and instructions do not follow the device thread either but Articles 46, 47 and 50 — Article 47 lists the mandatory items for secondary labels and Article 50 the mandatory items for instructions for use — and validity rests on Article 12, not Article 11. GRZAN repeatedly sees an inefficient approach: build the dossier skeleton on the device model, then swap in IVD content section by section, with classification logic, label fields and validity basis all misaligned at once, and a single deficiency round cannot fix everything.

The fifth judgment: the old technical-documentation entry point is closed. Article 69, item IX of RDC n° 830/2023 repeals IN n° 4/2012 in full as of June 1, 2024 — and that instruction had been the main basis on which companies organized technical documentation. Files still structured by it must be rearranged; the current anchor is Annex II of RDC n° 830/2023 itself. GRZAN builds a mapping table of old and new headings, marking the destination of each item so nothing is lost in the move.

One operational rule from GRZAN: decide whether a product is an IVD before every other action, not after the technical documentation is finished. The step costs almost nothing but determines the shape of the entire dossier. Beyond RDC n° 830/2023, an IVD must align horizontally with the optimized review of IN n° 290/2024, the data requirements of unique device identification (UDI) and the Brazilian UDI database (SIUD), and the essential safety and performance requirements of RDC n° 848/2024. Managing it as a system beside the device regime — rather than as one slice of a product line — is closer to how Brazil actually structures the field.

4. Practical recommendations

• Make the scope determination the first step of every project: separate the IVD and non-IVD product lists and never share one template.
• Plan backward from the June 1, 2024 effective date and check the status of the 365-day transition for unassayed QC products and nucleic acid extraction products.
• Schedule validity, starting point and revalidation rhythm under Article 12 of RDC n° 830/2023 — never cite Article 11 of RDC n° 751/2022.
• Build separate folders for analytical and clinical performance evidence, benchmarked to Article 81 of RDC n° 848/2024.
• For Class III/IV IVDs, assess the IN n° 290/2024 optimized review in parallel and compile foreign approval evidence early.
• Schedule UDI data and SIUD transmission duties together with the IVD project, not after registration is granted.
• Rearrange technical documentation to Annex II of RDC n° 830/2023 and stop following the repealed IN n° 4/2012 structure.

5. Verification checklist

• □ The effective date of June 1, 2024 under Article 71 of RDC n° 830/2023 has been confirmed
• □ The product has been confirmed to fall within the IVD scope of RDC n° 830/2023
• □ The status of the 365-day compliance window for unassayed QC and DNA/RNA extraction products has been checked
• □ The validity clause cited is Article 12, not Article 11 of RDC n° 751/2022
• □ Analytical and clinical performance evidence has been prepared in separate volumes

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides registration and compliance support for medical device and IVD manufacturers entering the Brazilian market, covering IVD scope determination, RDC n° 830/2023 dossier preparation, transition window management, UDI and SIUD data planning and post-market compliance. For assistance with Brazilian regulatory requirements, contact info@grzanglobal.com.